Moving away from metal: Step toward the future with bioresorbable vascular scaffolds and novel antiproliferative agents

Background: Peripheral arterial disease (PAD) is a common source of morbidity and mortality globally and is expected to raise increase in prevalence. Many endovascular techniques exist to manage PAD; however, there remains room for improvement, especially as it relates to below-the-knee vessels. Rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Blair E. Warren, MD, MSCS, Kong-Teng Tan, MD, Dheeraj K. Rajan, MD, Miranda Witheford, MD, PhD, Sean Crawford, MD, MSc, Arash Jaberi, MD, MEd, Sebastian Mafeld, MBBS
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JVS - Vascular Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666350324000889
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Peripheral arterial disease (PAD) is a common source of morbidity and mortality globally and is expected to raise increase in prevalence. Many endovascular techniques exist to manage PAD; however, there remains room for improvement, especially as it relates to below-the-knee vessels. Recent evidence and devices are leading to a resurgence of interest in bioresorbable vascular scaffolds and the -limus family of antiproliferative drugs in the PAD treatment space. Methods: This nonsystematic review examines emerging technology for treatment of PAD with a specific focus on below-the-knee vessels and bioresorbable vascular scaffolds. Additional emerging and early technology such as novel delivery platforms are also briefly discussed with directions of future research highlighted. Results: Bioresorbable vascular scaffold biomechanics and history are highlighted. Foundational knowledge of antiproliferative agents and evolving agents in peripheral vascular disease are also described. Conclusions: Bioresorbable vascular scaffolds are an additional endovascular tool for the treatment of peripheral vascular disease. The integration with an antiproliferative agent may result in improved patency and performance; however, there is a paucity of data in the literature at present.
ISSN:2666-3503